TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3569766
Drug: Cisapride (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (20 mg)
Study: 10531162
Drug: Grepafloxacin (GFX)
Normalized name: GREPAFLOXACIN
DrugBank: Grepafloxacin (DB00365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Grepafloxacin (GFX) 600 mg qd
Study: 10531162
Drug: Clarithromycin (CLA)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (CLA) 500 mg bid
Study: 29974545
Drug: Long cyberbullying
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long cyberbullying prevention program (10 weekly sessions)
Study: 24760262
Drug: HLA type
Normalized name: HLA type C IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLA type and number of positive antibodies
Study: 22966077
Drug: Glucose feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose feeding (1 g/(kg·d) for 3 d)
Study: 22966077
Drug: Fructose feeding
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fructose feeding (1 g/(kg·d) for 3 d)
Study: 9135272
Drug: Hypotonic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotonic oral rehydration solution (ORS)
Study: 1399929
Drug: High-dose ciprofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ciprofloxacin
Study: 3160356
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Atenolol + Nitrendipine)
Study: 21607780
Drug: i.v. paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. paracetamol 15 mg/kgBW
Study: 21607780
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of i.v. ketoprofen and i.v. paracetamol
Study: 21607780
Drug: Control (paracetamol)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (paracetamol)
Study: 18281734
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of omeprazole
Study: 18281734
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of omeprazole
Study: 18281734
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of ritonavir with 800 mg of indinavir and 40 mg of omeprazole
Study: 21296508
Drug: Extended-release zolpidem
Normalized name: zolpidem Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release zolpidem
Study: 9643668
Drug: Tamsulosin (TAM)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin (TAM) 0.4 mg once daily after breakfast for 15 days
Study: 8196850
Drug: Fluoxetin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetin (20 mg/die) and cyclobenzaprine (10 mg/die)
Study: 8196850
Drug: Cyclobenzaprine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine (10 mg/die)
Study: 3286577
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (400 mg three times a day on Days -6 to +14 and 200 mg three times a day on Days +15 to +90 for adults; 500 mg/m2 per day divided into three doses on Days -6 to +14 and 250 mg/m2 per day divided into three doses on Days +15 to +90 for children)
Study: 9593014
Drug: HDCV three-injection
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCV three-injection regimen
Study: 9593014
Drug: PVRV three-injection
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV three-injection regimen
Study: 9593014
Drug: Booster injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster injection at 1 year
Study: 19149880
Drug: Passive Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Physical Therapy (PPT)
Study: 12065553
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (MT) consisting of mercaptopurine and cytarabine for 18 months
Study: 12548362
Drug: Apo‐TD (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apo‐TD (transdermal apomorphine)
Study: 12548362
Drug: L‐dopa plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐dopa plus Apo‐TD
Study: 8030657
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone (group 1)
Study: 8030657
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous gammaglobulin (group 2)
Study: 8030657
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both agents (group 3)
Study: 31079356
Drug: Yimitasvir 400
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimitasvir 400 mg
Study: 31079356
Drug: Yimitasvir 100
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimitasvir 100 mg once daily for 7 days
Study: 31079356
Drug: Yimitasvir 200
Normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yimitasvir 200 mg once daily for 7 days
Study: 25223731
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg selisistat
Study: 24235227
Drug: Vectormune FP
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vectormune FP MG vaccination
Study: 21621660
Drug: Passive Treatment
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive Treatment
Study: 17033604
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0.9% 3x100 mL
Study: 9234031
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (AA) supplementation (1 g per day for two weeks)
Study: 3941213
Drug: OKY‐046, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY‐046, 400 mg/day orally
Study: 30125761
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks (TAC)
Study: 30125761
Drug: doxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks (ddAC)
Study: 26649909
Drug: Adductor Canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor Canal Block (ACB) with 30 mL ropivacaine 0.75% at t0 and 30 mL saline at t60
Study: 25022831
Drug: Ambulatory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory treatment (12 days of hospital visits over 6 months)
Study: 15867204
Drug: R-CHOP (rituximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP (rituximab 375 mg/m² + CHOP)
Study: 9705024
Drug: 5-HTP (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HTP (750 mg/d)
Study: 8539554
Drug: Lower antigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower antigen content vaccine (10 micrograms pertussis toxoid and 5 micrograms filamentous hemagglutinin)
Study: 11833825
Drug: Both vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccine formulations
Study: 2181857
Drug: Silicone-rubber balloon
Normalized name: CATHETER BALLOON SILICONE 18FR 5CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone-rubber balloon inflated with 400 mL for 1 month
Study: 18834910
Drug: Licensed ACWY
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed ACWY polysaccharide vaccine
Study: 7024020
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII) after 3 weeks of treatment
Study: 7579030
Drug: Caffeine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (60 mg)
Study: 25139268
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propofol + meperidine
Study: 25139268
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of midazolam + meperidine
Study: 14981104
Drug: Bilateral prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral prophylactic mastectomy with prior or concurrent bilateral prophylactic oophorectomy
Study: 30064718
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release (GXR) 1-7 mg/day; morning administration
Study: 18373710
Drug: Efalizumab 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 2 mg/kg weekly for 3 months
Study: 18373710
Drug: Efalizumab (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab (dosage not specified) during the optional transition period
Study: 10823256
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose intravenous UFH
Study: 10823256
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose subcutaneous LMWH Certoparin
Study: 1797193
Drug: 30 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m2 epirubicin weekly
Study: 1797193
Drug: 90 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/m2 epirubicin every 3 weeks
Study: 6344649
Drug: Oral ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ampicillin for 24 hours preceding and 3 days following surgery
Study: 329946
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic treatment
Study: 31982075
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg/day for 1 week, increasing to 50 mg/day for up to 12 months) plus usual care
Study: 22946768
Drug: Weekly pursed-lips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly pursed-lips breathing (PLB) reinforcement sessions via Skype for 4 weeks
Study: 19341357
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lecture and simulation
Study: 17617281
Drug: Hydrocodone/acetaminophen (H/A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone/acetaminophen (H/A) 5/500 mg
Study: 11408793
Drug: DA antagonist
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA antagonist (fluphenazine 2 mg)
Study: 8291866
Drug: Adjuvant prophylactic
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant prophylactic instillation treatments (local cytostatics and immunoagents)
Study: 16681880
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg/d
Study: 19809337
Drug: Quetiapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (up to 800 mg/day)
Study: 8685930
Drug: Maprotiline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (150 mg/d)
Study: 18853934
Drug: Zolpidem extended-release
Normalized name: zolpidem Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem extended-release 12.5 mg
Study: 9181646
Drug: Zidovudine 600
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 600 mg/day
Study: 9181646
Drug: Didanosine 400
Normalized name: didanosine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine 400 mg/day
Study: 30193294
Drug: Group-Administered Behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-Administered Behavioral Treatment (GBT)
Study: 15823767
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus metformin
Study: 24614911
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus glimepiride
Study: 24614911
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus glimepiride plus metformin
Study: 10351191
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human insulin-like growth factor I (rhIGF-I) therapy
Study: 1983500
Drug: Midazolam (0.2‐0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.2‐0.4 mg/kg/h)
Study: 1983500
Drug: Clonidin (1‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidin (1‐2 mg/d)
Study: 1983500
Drug: Alcohol substitution
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol substitution (1‐2 g/kg/d)
Study: 3544186
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 mg)
Study: 29080915
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab
Study: 21684606
Drug: Sham/0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham/0.5 mg group
Study: 10667640
Drug: MPFF 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 1000 mg/day for 6 weeks
Study: 10667640
Drug: MPFF 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 1000 mg/day for 2 months
Study: 10667640
Drug: MPFF 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPFF 1000 mg once daily or bid for 2 months
Study: 1298597
Drug: Individualized administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized administration of gentamicin
Study: 1298597
Drug: Conventional administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional administration of gentamicin
Study: 15082469
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg/day
Study: 17397098
Drug: Antipsychotic (AP)
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic (AP) polypharmacy
Study: 17397098
Drug: Typical AP
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical AP drugs
Study: 17397098
Drug: Clozapine and
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine and atypical and oral AP
Study: 16288613
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg morphine (group BM0.1)
Study: 17197846
Drug: ADVANCE (family-centered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADVANCE (family-centered behavioral preparation)
Study: 7908164
Drug: Ibopamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibopamine (100 mg, 3 times/day)
Study: 19384186
Drug: Calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitor (CNI)
Study: 29488482
Drug: Ursosan (UDCA)
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursosan (UDCA) 15 mg/kg for 24 weeks
Study: 2140095
Drug: Nisoldipine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine (0.5 mg)
Study: 24510176
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 200 μg once daily for 8 weeks
Study: 24510176
Drug: Oral clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clarithromycin 500 mg twice daily for 2 weeks, then 250 mg once daily for 6 weeks, plus mometasone furoate
Study: 24510176
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (clarithromycin + mometasone)
Study: 17917441
Drug: Multinational norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multinational norfloxacin tablet (Noroxin)
Study: 15842025
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus a systematic care management program including initial assessment, monthly telephone monitoring, feedback to treatment team, and structured group psychoeducational program provided by a nurse care manager.
Study: 12197593
Drug: Esmolol group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol group (intravenous esmolol drip during CPB to maintain heart rate at 30‐50 beats/min)
Study: 41546
Drug: Glutethimide 500
Normalized name: glutethimide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutethimide 500 mg
Study: 16377449
Drug: Daily IVR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IVR reporting with personal follow-up on noncompliant callers
Study: 16377449
Drug: Daily IVR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily IVR reporting without follow-up
Study: 14529670
Drug: Carboplatin (AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (AUC 6), followed by paclitaxel (175 mg/m(2) over 3 h) (C-P)
Study: 14529670
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m(2) over 3 h), followed by carboplatin (AUC 6) (P-C)
Study: 10923634
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (6 mg/kg over 1 min every 10 min)
Study: 8753109
Drug: G-CSF (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (50 microns/m2, subcutaneously) administered when leukocyte count is ≤ 1000/mm3
Study: 8753109
Drug: G-CSF (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (50 microns/m2, subcutaneously) administered when leukocyte count is between 1000/mm3 and 2000/mm3
Study: 21307009
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 µg kg(‐1) i.v. over 20 min followed by 0.7 µg kg(‐1) h(‐1) infusion for 190 min)
Study: 21307009
Drug: Morphine hydrochloride
Normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine hydrochloride (0.10 mg kg(‐1) i.v. over 20 min)
Study: 28030444
Drug: Sugammadex (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2.0 mg/kg)
Study: 3516510
Drug: Diphenhydramine 100
Normalized name: acetaminophen-diphenhydramine 1000 mg-50 mg/30 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 100 mg
Study: 11314681
Drug: Lorazepam 1.5
Normalized name: lorazepam 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 1.5 mg
Study: 16401664
Drug: Diphenhydramine (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (50, 75, and 100 mg)
Study: 10757250
Drug: Lorazepam 0.5
Normalized name: lorazepam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 0.5 mg
Study: 9924298
Drug: 99mTc‐carbon gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc‐carbon gel
Study: 7752839
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule containing 100 mg of CoQ with 400 mg of soy bean oil (Bioquinon)
Study: 7752839
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule containing 100 mg of CoQ with 20 mg of polysorbate 80 and 380 mg of soy bean oil
Study: 31161926
Drug: Audiobook (AB)
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audiobook (AB) placebo treatment
Study: 24841502
Drug: Ultrasound-assisted epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-assisted epidural steroid injections
Study: 24841502
Drug: Fluoroscopic-guided epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopic-guided epidural steroid injections
Study: 16579998
Drug: Measurements of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measurements of serum insulin, leptin, sOB-R at fasting and during a standard oral glucose tolerance test (OGTT)
Study: 12061352
Drug: Ibuprofen-arginine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen-arginine (1 drop/kg: 6.67 mg/kg)
Study: 12061352
Drug: Paracetamol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (4 drops/kg: 10.65 mg/kg)
Study: 9207871
Drug: Ibuprofen-arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen-arginine
Study: 7771617
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg LMWH (enoxaparin) once daily
Study: 2313607
Drug: Non-insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-insulin-dependent diabetes (diet, tablet, or ultralente insulin therapy)
Study: 6342565
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amitriptyline hydrochloride, up to 150 mg/day, and tranylcypromine, up to 20 mg/day
Study: 16329018
Drug: Meperidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 0.5 mg/kg intravenously (group 1)
Study: 15734603
Drug: Tibolone 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 5.0 mg
Study: 15734603
Drug: Tibolone 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 0.625 mg
Study: 15734603
Drug: Tibolone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (all doses)
Study: 7768667
Drug: Adrenocorticotropic hormone
Normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adrenocorticotropic hormone (ACTH) administration
Study: 2179769
Drug: Ticlopidine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (500 mg per diem for 15 days)
Study: 380742
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous heparin (5000 IU eight-hourly)